Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients...
2025-03-06 7:30 AM EST
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announces the sale of 15 ACP-01 Therapy...
2025-03-05 7:45 AM EST
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect...
2025-02-20 6:05 AM EST
Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect...
2025-02-19 3:24 PM EST
Hemostemix Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investment Regulatory Organization ("CIRO"), it is issuing this news release to clarify and provide additional information regarding its previous announcement dated February 10, 2025. On February 10, 2025, Hemostemix announced the engagement of Proconsul Capital Ltd. to provide investor relations...
2025-02-13 8:09 PM EST
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification from the International Air Transport Association (IATA). This milestone reinforces Puerto Rico's status as a global leader in the logistics of biologics and pharmaceutical products. The CEIV Pharma Certification ensures the highest standards in the handling, storage, and transportation of...
2025-02-11 9:43 AM EST
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital Ltd. ("ProConsul"), to provide investment marketing consulting services (the "Services") commencing February 6th, 2025. In consideration for the Services, the Company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the stock options...
2025-02-10 10:48 AM EST
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares
Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at today's closing price of $0.295 ($336,500 / $0.69789 = $482,167.68) (1,634,466 Common Shares), subject to the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. "The Hemostemix technology...
2025-02-04 5:16 PM EST
Hemostemix Expands to the Dominican Republic
Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company brings its revolutionary ACP-01 therapy back to the Dominican Republic. Hemostemix has posted an update on Social Media, sharing an inside look at its latest initiative in the Dominican Republic, with a team of cardiologists who have the capacity to treat 110 patients per month. This team of...
2025-02-03 12:57 PM EST
Hemostemix Announces First Sales Orders for ACP-01
Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatments are gaining traction, following its social media campaign and presentations in Puerto Rico. "Advanced sales of ACP-01 enables the purchaser/patient to understand if they are patient one, 10, or 500, and that certainty is helpful," stated Thomas Smeenk, Hemostemix, CEO. "Advanced sales...
2025-01-29 2:11 PM EST
Hemostemix Up-lists to TradeGateExchange in Germany
Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares commenced trading on the TradeGateExchange.De under symbol 2VF0 today, January 27, 2025. "Listing on the TradeGateExchange.De enables Hemostemix to investors in the Europe, the EU, UK, to buy into their Fountain of Youth and longevity, directly. As management and directors, we have invested greater than $9.1...
2025-01-27 2:37 PM EST
Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico
Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares will commence trading on the OTCQB under symbol HMTXF today, January 23, 2025, while the Company presents "Welcome to Your Fountain of Youth!" at the Sequire Investor Summit at 11:00 a.m. "Listing on the OTCQB enables US investors to buy into their 'Fountain of Youth' and longevity, directly. As an investor...
2025-01-23 8:27 AM EST
Hemostemix Announces Grant of Stock Options
Calgary, Alberta--(Newsfile Corp. - January 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on January 22, 2025, subject to regulatory approval, a total of 2,085,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 1,815,000 vest immediately and 270,000...
2025-01-22 12:14 AM EST
Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
Calgary, Alberta--(Newsfile Corp. - January 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is proud to announce its participation in two highly anticipated Puerto Rico Investor Summits: Sequire Investor Summit: January 22-23 at the Condado Vanderbilt Hotel. CytoImmune-hosted Event: January 24 at CytoImmune's state-of-the-art facility in San Juan, Puerto Rico. Thomas Smeenk, President & CEO of Hemostemix, will deliver an engaging presentation...
2025-01-20 8:54 AM EST
Hemostemix Settlement via Depository Trust Company Plus OTCQB Update
Calgary, Alberta--(Newsfile Corp. - January 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that the settlement of Hemostemix common share purchases via the Depository Trust Company ("DTC") is now enabled. The Company filed a disclosure document with OTC Markets on Wednesday, January 7, 2025. Hemostemix expects to receive OTCIQ access this week. Upon receipt, the Company will upload its financial statements and MD&A, with...
2025-01-13 9:09 AM EST
Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up
Calgary, Alberta--(Newsfile Corp. - January 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) is pleased to announce amendments to its Manufacturing Services Agreement with CytoImmune Therapeutics ("CytoImmune"). These amendments add Regulatory Consulting and Engineering Services and align payments made by Hemostemix PR Inc. with the policies of both the TSX Venture Exchange and Puerto Rico's ACT 60 Program. Driving Regulatory and Engineering Innovation CytoImmune's regulatory...
2025-01-09 8:36 AM EST
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash
Calgary, Alberta--(Newsfile Corp. - January 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has incorporated Hemostemix PR Inc., in Puerto Rico, as a wholly owned subsidiary and a domestic for profit corporation. Under Puerto Rico's ACT 60 program, Hemostemix PR Inc. is eligible to file applications for cash reimbursement of up to 50% of its research and development expenses, including clinical trials, economic impact...
2025-01-06 9:10 AM EST
Hemostemix is Up-Listing in the USA to Generate Liquidity
Calgary, Alberta--(Newsfile Corp. - January 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has applied to up-list its shares on the OTCQB Venture Market. Currently listed on the TSXV Exchange, Frankfurt, and the OTC, Hemostemix aims to increase its liquidity by broadening its reach to all investors who trade in the capital markets of the USA, Europe, and Canada. The Company's social media campaign across Instagram,...
2025-01-02 9:10 AM EST
Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction
Calgary, Alberta--(Newsfile Corp. - December 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X is gaining traction. This campaign aims to share patient success stories, connect with individuals seeking safe and innovative treatments for no-option cardiovascular diseases, and educate the public about Hemostemix as an investment opportunity....
2024-12-31 2:50 PM EST
Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments
Calgary, Alberta--(Newsfile Corp. - December 17, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the launch of its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X. This campaign aims to share patient success stories, connect with individuals seeking safe and innovative treatments for no-option cardiovascular diseases, and educate the public about Hemostemix as an investment opportunity. Follow...
2024-12-17 11:12 AM EST